HIMS is trading at $24.38 (-16%) in pre-market following a Q1 2026 earnings miss and a strategic pivot toward lower-margin branded GLP-1 medications.
- The company reported revenue of $608.1M (vs. $616.9M expected) and a $0.40 net loss per share, reflecting a partnership with Novo Nordisk aimed at prioritizing regulatory stability over short-term margins.
- Despite the bottom-line miss, management raised full-year 2026 revenue guidance to a range of $2.8B–$3.0B.
- Shares are extending a sell-off from the previous close of $29.14, with additional pressure stemming from broader market weakness.